US Patent

US9187495 — Compounds and methods for treating bacterial infections

Method of Use · Assigned to Entasis Therapeutics Ltd · Expires 2034-01-21 · 8y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent discloses compounds and their uses for treating bacterial infections.

USPTO Abstract

Compounds of formula (I), pharmaceutically acceptable salts thereof, and uses of the compounds of formula (I) for treating bacterial infections are disclosed.

Drugs covered by this patent

zoliflodacin (ZOLIFLODACIN)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-4369`	—	zoliflodacin

Patent Metadata

Patent number: US9187495
Jurisdiction: US
Classification: Method of Use
Expires: 2034-01-21
Drug substance claim: Yes
Drug product claim: No
Assignee: Entasis Therapeutics Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.